Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Transplacental passage of protease inhibitors at delivery
AIDS, Volume 16, No. 6, Year 2002
Notification
URL copied to clipboard!
Description
Objective: Although combinations of different antiretroviral drugs are increasingly used by pregnant HIV-1-infected women, few human data are available to evaluate in utero protease inhibitors (PI) exposure. The aim of this study was to assess the extent of transplacental passage of PI at delivery. Methods: Pregnant women treated with antiretroviral drugs including PI and/or nevirapine were eligible for the study. Placental transfer was determined by comparison of drug concentrations in blood samples simultaneously collected from a peripheral maternal vein and the umbilical cord at delivery. Drug levels were determined by high-performance liquid chromatography. Results: Thirteen maternal-cord blood sample pairs were evaluable for transplacental passage determination (nine nelfinavir, two ritonavir, one saquinavir, one lopinavir, two nevirapine). Median cord and maternal drug concentrations, respectively, were nelfinavir < 250 and 1110 ng/ml; ritonavir < 250 and 1113 ng/ml; saquinavir < 100 and 350 ng/ml; lopinavir < 250 and 3105 ng/ml and nevirapine 2072 and 2546 ng/ ml. The cord-to-maternal blood ratio was extremely low for all PI. Conclusion: PI do not cross the placenta to an appreciable extent and consequently cannot be expected to exert a direct antiviral activity in utero during the whole dosing interval. Limited transfer may result from their high degree of plasma protein binding and their backwards transport through P-glycoprotein, largely expressed in the placenta. In contrast, nevirapine readily crosses the placental barrier. Such considerations may support treatment decisions in pregnant women. © 2002 Lippincott Williams & Wilkins.
Authors & Co-Authors
Marzolini, Catia
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Rudin, Christoph
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Décosterd, Laurent Arthur
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Telenti, Amalio
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Buclin, Thierry J.
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Battegay, Manuel
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Bernasconi, Enos
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Biedermann, Kurt J.
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Bucher, Heíner C.C.
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Bürgisser, Ph
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Egger, Matthias
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Erb, Peter
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Flepp, Markus J.
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Francioli, Patrick B.
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Furrer, Hansjakob
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Gorgievski, Meri
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Günthard, Hüldrych Fritz
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Grob, Peter J.
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Hirschel, B. J.
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Hösli, Irene Mathilde
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Kind, Christian H.
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Klimkait, Thomas
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Nadal, David
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Opravil, Milos
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Paccaud, Fred Michel
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Pantaleo, Giuseppe P.
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Perrin, Luc Henri
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Piffaretti, Jean Claude L.
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Rickenbach, Martin
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Schüpbach, Jörg Rg
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Vernazza, Pietro Luigi
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Weber, Rainer
Switzerland, Lausanne
Centre Hospitalier Universitaire Vaudois
Statistics
Citations: 100
Authors: 32
Affiliations: 1
Identifiers
Doi:
10.1097/00002030-200204120-00008
ISSN:
02699370
Research Areas
Infectious Diseases
Maternal And Child Health
Participants Gender
Female